IGF-1 LR3 vs IGF-1 DES is an important comparison in insulin-like growth factor research. Both are modified forms of insulin-like growth factor-1 (IGF-1), but they differ in amino acid composition, molecular structure, interactions with IGF-binding proteins, and experimental biological activity.
IGF-1 LR3, also known as Long R3 IGF-I, is an engineered 83-amino-acid analogue developed with an additional N-terminal sequence and an arginine substitution.
IGF-1 DES, commonly called des(1-3) IGF-1, is a shorter 67-amino-acid variant missing the first three residues of naturally occurring IGF-1.
Although both compounds exhibit reduced affinity for IGF-binding proteins (IGFBPs), the modifications responsible for this characteristic are different.
Understanding these differences is essential when evaluating research involving IGF-1 receptor signaling, cellular proliferation, and growth-factor bioavailability.
This article compares their structures, receptor interactions, published studies, biological activity, and research limitations.
For compound-specific information, see Orion Peptides’ IGF-1 LR3 1mg research material.
What Is IGF-1 LR3?
IGF-1 LR3 is a synthetic analogue of human insulin-like growth factor-1.
Naturally occurring mature IGF-1 contains 70 amino acids and participates in the regulation of cellular growth, development, metabolism, and tissue signaling.
Researchers developed IGF-1 LR3 by modifying the native IGF-1 sequence.
The modifications include:
- Replacing glutamic acid at position three with arginine.
- Adding a 13-amino-acid extension to the N-terminus.
These changes produce an 83-amino-acid analogue with reduced affinity for several IGF-binding proteins.
IGF-1 LR3 retains activity at the IGF-1 receptor, making it useful in experiments examining receptor-mediated biological responses.
Its altered binding-protein interactions are particularly relevant to laboratory investigations involving cellular signaling and growth-factor availability.
Researchers can explore the IGF-1 LR3 1mg compound specifications for additional information about the research material.
What Is IGF-1 DES?
IGF-1 DES, also known as des(1-3) IGF-I, is a truncated variant of naturally occurring insulin-like growth factor-1.
Unlike IGF-1 LR3, which includes an extended amino acid sequence, IGF-1 DES is formed by removing three residues from the N-terminus of native IGF-1.
The missing residues are:
- Glycine.
- Proline.
- Glutamic acid.
This produces a 67-amino-acid peptide.
Is IGF-1 DES Naturally Occurring?
Yes. Des(1-3) IGF-I has been identified in biological tissues.
A scientific review published by Ballard and colleagues in 1996 described its isolation from bovine colostrum, human brain, and porcine uterus.
The authors suggested that the peptide may arise through post-translational cleavage of IGF-1.
This distinguishes naturally occurring IGF-1 DES from the engineered Long R3 analogue.
The research also described reduced binding to IGFBPs and increased potency in certain cell-culture experiments.
Read the original scientific review on PubMed.
IGF-1 LR3 vs IGF-1 DES: Key Differences
Both peptides are modified forms of IGF-1, but their structures and experimental properties differ.
| Property | IGF-1 LR3 | IGF-1 DES |
|---|---|---|
| Full name | Long R3 IGF-I | Des(1-3) IGF-I |
| Amino acid residues | 83 | 67 |
| Parent protein | Native IGF-1 | Native IGF-1 |
| Molecular modification | Arg3 substitution and N-terminal extension | Removal of first three residues |
| Molecular architecture | Extended analogue | Truncated analogue |
| Naturally occurring form | No | Yes, identified in biological tissues |
| IGFBP affinity | Substantially reduced | Substantially reduced |
| IGF1R activity | Retained | Retained |
| Principal research interest | IGFBP interactions and receptor signaling | IGFBP regulation and cellular responses |
| FDA approval | Not approved | Not approved |
These distinctions demonstrate why findings involving one analogue should not automatically be applied to the other.
1. Molecular Structure: How Are IGF-1 LR3 and IGF-1 DES Different?
The most fundamental difference between IGF-1 LR3 and IGF-1 DES is their amino acid sequence.
IGF-1 LR3 Molecular Structure
IGF-1 LR3 contains 83 amino acids.
Its structural changes occur near the N-terminal region of the original IGF-1 molecule.
The substitution of arginine at position three and the additional 13 residues modify interactions with IGF-binding proteins.
These modifications are important because binding proteins regulate the distribution and availability of insulin-like growth factors.
The altered structure enables researchers to examine IGF-related activity under conditions where normal IGFBP regulation is reduced.
IGF-1 DES Molecular Structure
IGF-1 DES is shorter than native IGF-1.
Its sequence begins after the first three amino acids of the native molecule have been removed.
The loss of the N-terminal tripeptide changes interactions with IGF-binding proteins while preserving activity at IGF1R.
This allows researchers to investigate how the N-terminal region contributes to growth-factor regulation.
Why Do These Structural Changes Matter?
Small changes in amino acid composition can significantly affect protein interactions.
Both analogues demonstrate that the N-terminal region of IGF-1 contributes to its interactions with binding proteins.
However, the biological effects of those modifications depend on the experimental conditions and the receptor systems being examined.
For broader information about peptide structural modifications and growth-factor signaling, see the IGF-1 Proteins research category at Orion Peptides.
2. IGF-1 LR3 vs IGF-1 DES: Receptor Binding
Both compounds retain the ability to interact with the insulin-like growth factor-1 receptor.
IGF1R is a transmembrane receptor tyrosine kinase that participates in the regulation of cellular growth, differentiation, survival, and metabolism.
When IGF1R is activated, intracellular signaling pathways can influence several biological processes.
IGF-1 LR3 Receptor Activity
IGF-1 LR3 retains receptor-binding activity despite its structural modifications.
Its reduced affinity for IGFBPs can increase the availability of the analogue to interact with receptors in particular laboratory conditions.
This distinction is especially important in cell-culture systems containing different concentrations of binding proteins.
IGF-1 DES Receptor Activity
IGF-1 DES also retains IGF1R-binding activity.
Research has demonstrated that removing the N-terminal tripeptide substantially changes binding-protein interactions without eliminating IGF1R activity.
A 2002 study by Forbes and colleagues used surface plasmon resonance to examine interactions between IGF analogues and IGF1R.
The researchers found that des(1-3) IGF-I and several other analogues retained receptor-binding affinities relatively similar to native IGF-I.
Read the receptor-binding study.
Does One Analogue Bind More Strongly to IGF1R?
Available research does not support a universal ranking applicable to every experimental system.
Differences in measured biological potency often arise from altered interactions with IGFBPs rather than dramatically stronger IGF1R binding.
This is an important distinction when interpreting laboratory results.
3. What Are IGF-Binding Proteins?
IGF-binding proteins are regulatory proteins that interact with insulin-like growth factors.
They influence growth-factor distribution, bioavailability, and biological activity.
The IGF-binding protein family includes six principal high-affinity IGFBPs.
These proteins can modify how much IGF is available to interact with cellular receptors.
Why Are IGFBPs Important?
In many physiological environments, IGF-1 exists in association with binding proteins.
These interactions can influence:
- Growth-factor transport.
- Extracellular availability.
- Receptor accessibility.
- Protein clearance.
- Tissue-specific biological responses.
IGF-binding proteins may inhibit or enhance biological activity depending on the specific protein and experimental context.
IGF-1 LR3 and IGFBPs
IGF-1 LR3 was engineered to reduce interactions with these binding proteins.
The N-terminal extension and Arg3 substitution substantially reduce binding affinity for several IGFBPs.
This property makes the analogue useful for experiments examining IGF1R signaling with reduced binding-protein regulation.
IGF-1 DES and IGFBPs
IGF-1 DES also exhibits reduced IGFBP affinity, but through truncation rather than sequence extension.
In a 1989 study, Ross and colleagues investigated interactions between IGF-binding proteins and different IGF analogues.
The researchers found that certain IGFBPs inhibited biological responses to native IGF-1 and IGF-2 but did not similarly inhibit des(1-3) IGF-I.
This finding helped demonstrate the importance of IGFBP interactions in regulating cellular responses.
4. Biological Potency: Is IGF-1 DES Stronger Than IGF-1 LR3?
A common question in IGF analogue research concerns comparative biological potency.
However, the meaning of potency depends on the biological endpoint being measured.
For example, researchers may examine:
- Receptor-binding affinity.
- Cell proliferation.
- DNA synthesis.
- Protein accumulation.
- Metabolic responses.
- Tissue-specific effects.
Results from one experimental system cannot be automatically generalized to another.
IGF-1 DES Potency in Cell Culture
The 1996 review by Ballard and colleagues reported that des(1-3) IGF-I was generally about ten times more potent than native IGF-I at stimulating selected hypertrophic and proliferative responses in cultured cells.
This greater activity was associated with reduced IGFBP binding.
Importantly, the comparison was made under specific laboratory conditions.
It does not establish that IGF-1 DES is ten times more effective in humans.
IGF-1 LR3 Experimental Activity
IGF-1 LR3 has also demonstrated enhanced biological activity relative to native IGF-1 in certain experimental systems.
Its reduced binding-protein affinity can influence how much analogue remains accessible to receptors.
However, the magnitude of the effect varies depending on the model, receptor expression, and IGFBP environment.
Which Is More Potent?
Neither compound can be described as universally more potent.
The most scientifically accurate conclusion is that both analogues can exhibit increased biological activity relative to native IGF-1 in specific laboratory systems because of altered IGFBP interactions.
Direct comparisons require attention to the experimental model and measured endpoint.
5. IGF-1 LR3 vs IGF-1 DES: Pharmacokinetics and Clearance
Pharmacokinetics describes how a compound is distributed, metabolized, and cleared within a biological system.
IGF-binding proteins can influence these processes.
Does IGF-1 LR3 Have a Longer Half-Life?
IGF-1 LR3 is sometimes described as a long-acting IGF analogue.
However, the name “Long R3” refers to its extended molecular structure, not a proven long circulating half-life in humans.
A study by Ballard and colleagues examined IGF analogues with modified IGFBP interactions.
The researchers reported that LR3 IGF-I cleared from rat plasma more rapidly than native IGF-I.
This demonstrates that reduced IGFBP binding and greater biological potency do not necessarily produce prolonged circulation.
Read the comparative clearance study.
What About IGF-1 DES?
IGF-1 DES also has reduced binding affinity for IGFBPs.
Animal research has examined how this property affects distribution, clearance, and metabolic responses.
However, the available evidence does not establish a reliable clinical half-life for human use.
Are the Commonly Quoted Half-Life Values Reliable?
Specific circulating half-life figures are frequently repeated online for both analogues.
Those values should not be treated as established human pharmacokinetic parameters without appropriate clinical evidence.
The effects of molecular structure and binding-protein interactions on clearance are more complex than a simple comparison of peptide length.
6. IGF-1 LR3 vs IGF-1 DES: What Do Animal Studies Show?
Several animal studies have compared IGF-1 analogues with reduced IGFBP binding.
Comparative Glucose-Lowering Research
A 1998 study published in the Journal of Endocrinology investigated insulin-like growth factor variants in pigs and marmoset monkeys.
Researchers compared native IGF-I with analogues that included des(1-3) IGF-I and LR3 IGF-I.
The study examined changes in plasma glucose and related pharmacological responses.
Main Findings
The investigators found that the modified IGF analogues were generally more potent than native IGF-I at lowering plasma glucose in the examined animal models.
The analogues demonstrated approximately two- to threefold greater potency for the measured glucose endpoint.
The relative potency ranking included higher activity for des(1-3) IGF-I than LR3 IGF-I in that particular experimental comparison.
However, these results were specific to the species and metabolic endpoint studied.
They do not establish a clinical ranking for muscle growth or other human outcomes.
Read the animal comparison study.
7. Cellular Growth and Proliferation Research
Both IGF-1 LR3 and IGF-1 DES have been investigated in experimental systems involving cellular proliferation and tissue responses.
IGF-1 LR3 in Cell Signaling Research
Researchers use IGF-1 LR3 in experiments examining the relationship between growth-factor availability and receptor-mediated cellular activity.
Areas of investigation include:
- Cellular proliferation.
- Protein synthesis pathways.
- Growth-factor receptor signaling.
- IGFBP regulation.
- Cell survival and differentiation.
IGF-1 DES in Cell-Culture Models
IGF-1 DES has been used to examine cellular responses in environments containing IGF-binding proteins.
In 1992, researchers published a study in the Journal of Clinical Investigation examining the role of IGFBPs in granulosa-cell hormone signaling.
They found that des(1-3) IGF-I demonstrated greater potency than native IGF-I under binding-protein-rich conditions.
However, the difference was substantially reduced when the experimental environment lacked those binding proteins.
This finding supported the conclusion that reduced IGFBP interactions, rather than universally greater receptor potency, explained much of the observed effect.
Read the 1992 study in the Journal of Clinical Investigation.
8. IGF-1 LR3 vs IGF-1 DES: Safety and Research Limitations
Neither IGF-1 LR3 nor IGF-1 DES is FDA approved for human therapeutic administration.
The available literature consists predominantly of laboratory and animal research.
Both analogues interact with biological pathways involved in glucose regulation and cellular proliferation.
These pathways require careful scientific consideration because their effects extend beyond a single tissue or biological function.
Potential Safety Concerns
Experimental findings raise concerns involving:
Glucose regulation: Modified IGF analogues have demonstrated significant glucose-lowering activity in animal studies.
Cellular proliferation: IGF1R signaling participates in growth-related processes, making uncontrolled stimulation a relevant safety concern.
Uncertain long-term effects: Adequate controlled human studies have not established long-term safety for either analogue.
Differences between experimental materials: Findings may vary depending on molecular identity, formulation, analytical quality, and experimental conditions.
Can Findings From Native IGF-1 Be Applied to These Analogues?
Not automatically.
Although both compounds retain many biological characteristics of IGF-1, their altered binding-protein interactions can change experimental behavior.
The safety profile of a pharmaceutical containing another form of IGF-1 cannot establish the safety of IGF-1 LR3 or IGF-1 DES.
9. IGF-1 LR3 and IGF-1 DES in Laboratory Research
Both analogues are relevant to investigations of insulin-like growth factor biology.
However, their distinct molecular modifications make them useful for examining different questions about growth-factor regulation.
Research Involving IGF-1 LR3
IGF-1 LR3 is particularly relevant when researchers want to investigate the effects of an extended IGF analogue with reduced IGFBP interactions.
Experiments may examine receptor signaling, cellular responses, and growth-factor bioavailability.
Orion Peptides provides IGF-1 LR3 1mg compound documentation, including compound information and laboratory analytical findings.
Research Involving IGF-1 DES
IGF-1 DES is particularly relevant to studies examining how the N-terminal region of native IGF-1 influences IGFBP affinity.
Because it is a truncated variant, it provides a distinct experimental model for investigating binding-protein regulation.
Why Is Research-Material Quality Important?
For either analogue, appropriate experimental interpretation depends on reliable molecular characterization.
Analytical methods may include high-performance liquid chromatography and mass spectrometry.
Researchers should consider batch-specific documentation when assessing identity and purity.
Orion Peptides maintains a COA Verification Library for research-material testing information.
Analytical documentation does not establish that a compound is safe or approved for human administration.
10. Which IGF-1 Analogue Has More Scientific Evidence?
Both IGF-1 LR3 and IGF-1 DES have been investigated in the scientific literature.
However, the available evidence differs in the experimental systems and research questions addressed.
IGF-1 LR3 has been studied extensively as an engineered analogue with reduced IGFBP binding.
IGF-1 DES has been investigated as a truncated form of IGF-1 with altered binding-protein interactions and enhanced activity in certain cellular models.
Neither has a sufficient human clinical evidence base to support general therapeutic claims.
Therefore, the compounds should be compared according to their established molecular properties and specific experimental findings rather than unsupported claims about clinical superiority.
Frequently Asked Questions
What is the main difference between IGF-1 LR3 and IGF-1 DES?
IGF-1 LR3 is an 83-amino-acid analogue with an N-terminal extension and Arg3 substitution. IGF-1 DES is a 67-amino-acid truncated analogue missing the first three residues of native IGF-1.
Is IGF-1 DES stronger than IGF-1 LR3?
Some animal experiments have reported greater potency for des(1-3) IGF-I in specific metabolic endpoints. However, the findings do not establish universal superiority or greater clinical effectiveness.
Does IGF-1 LR3 bind to IGF-binding proteins?
Yes, but its affinity for several IGFBPs is substantially reduced compared with native IGF-1.
Why does IGF-1 DES have reduced IGFBP affinity?
The removal of the N-terminal tripeptide changes molecular interactions important for binding-protein recognition.
Is IGF-1 LR3 longer-lasting than IGF-1 DES?
There is insufficient human pharmacokinetic evidence to establish a reliable comparison of their duration of action. Common online half-life claims should be interpreted cautiously.
Is IGF-1 DES naturally occurring?
Yes. Des(1-3) IGF-I has been identified in biological tissues and may arise through post-translational processing of native IGF-1.
Are IGF-1 LR3 and IGF-1 DES FDA approved?
No. Neither analogue is FDA approved for human therapeutic administration.
Are these compounds the same as human growth hormone?
No. They are modified forms of IGF-1, not human growth hormone. Although growth hormone and IGF-1 participate in related endocrine pathways, they are distinct molecules with different receptor interactions.
Conclusion
The comparison of IGF-1 LR3 vs IGF-1 DES demonstrates how different structural modifications can alter the biological properties of insulin-like growth factor-1.
IGF-1 LR3 is an engineered 83-amino-acid analogue containing an Arg3 substitution and an N-terminal extension.
IGF-1 DES is a 67-amino-acid truncated variant that lacks the first three residues of native IGF-1.
Both compounds show reduced affinity for IGF-binding proteins while retaining IGF receptor activity.
Published studies have demonstrated increased biological potency in selected laboratory and animal models, but the results vary depending on experimental conditions and measured endpoints.
Neither compound has an established human therapeutic safety profile.
Understanding their molecular differences, receptor interactions, and research limitations is essential for accurate interpretation of the available scientific literature.
Scientific References
- Ballard FJ et al. (1996). Des(1–3)IGF-I: A Truncated Form of Insulin-Like Growth Factor-I. International Journal of Biochemistry & Cell Biology. PubMed.
- Ross M et al. (1989). Insulin-Like Growth Factor (IGF)-Binding Proteins Inhibit the Biological Activities of IGF-1 and IGF-2 but Not des-(1-3)-IGF-1. Biochemical Journal. Full-text article.
- Lord AP et al. (1994). Transfer of Insulin-Like Growth Factor (IGF)-I From Blood to Intestine: Comparison With IGFs That Bind Poorly to IGF-Binding Proteins. Journal of Endocrinology. PubMed.
- Forbes BE et al. (2002). Characteristics of Binding of Insulin-Like Growth Factor (IGF)-I and IGF-II Analogues to the Type 1 IGF Receptor Determined by BIAcore Analysis. European Journal of Biochemistry. Original study.
- Ballard FJ et al. (1993). Effects of Interactions Between IGFBPs and IGFs on the Plasma Clearance and In Vivo Biological Activities of IGFs and IGF Analogs. PubMed.
- IGF-I Variants Which Bind Poorly to IGF-Binding Proteins Show More Potent and Prolonged Hypoglycaemic Action Than Native IGF-I in Pigs and Marmoset Monkeys. (1998). PubMed.
- Granulosa Cell-Derived Insulin-Like Growth Factor Binding Proteins Are Inhibitory to IGF-I Hormonal Action. (1992). Journal of Clinical Investigation. Full-text study.
Research disclaimer: This article is intended exclusively for scientific and educational purposes. IGF-1 LR3 and IGF-1 DES are investigational compounds and are not approved for human or veterinary therapeutic use. The article does not provide medical advice or recommend administration of either compound.
